Polaris Chemical

Polaris Group is a multinational biopharmaceutical company specializing in the development of novel metabolic therapies for cancer. The company's lead product candidate, ADI-PEG 20 (pegargiminase), is a recombinant enzyme that targets arginine-auxotrophic tumors by depleting the external supply of arginine. Polaris is currently advancing ADI-PEG 20 through late-stage clinical trials for indications including malignant pleural mesothelioma and hepatocellular carcinoma. With vertically integrated capabilities, the company maintains research and manufacturing facilities in both the United States and Taiwan to support its global clinical programs.